Iterum Therapeutics (ITRM) EBIAT (2017 - 2022)
Historic EBIAT for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$5.1 million.
- Iterum Therapeutics' EBIAT fell 2171.21% to -$5.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$44.4 million, marking a year-over-year increase of 5147.22%. This contributed to the annual value of -$24.8 million for FY2024, which is 3543.56% up from last year.
- Iterum Therapeutics' EBIAT amounted to -$5.1 million in Q4 2022, which was down 2171.21% from -$29.1 million recorded in Q3 2022.
- In the past 5 years, Iterum Therapeutics' EBIAT ranged from a high of $7.8 million in Q2 2021 and a low of -$98.9 million during Q1 2021
- Over the past 5 years, Iterum Therapeutics' median EBIAT value was -$14.1 million (recorded in 2018), while the average stood at -$18.4 million.
- In the last 5 years, Iterum Therapeutics' EBIAT surged by 16227.94% in 2021 and then tumbled by 87810.75% in 2022.
- Iterum Therapeutics' EBIAT (Quarter) stood at -$24.3 million in 2018, then increased by 2.54% to -$23.6 million in 2019, then skyrocketed by 52.68% to -$11.2 million in 2020, then skyrocketed by 62.61% to -$4.2 million in 2021, then dropped by 21.71% to -$5.1 million in 2022.
- Its EBIAT was -$5.1 million in Q4 2022, compared to -$29.1 million in Q3 2022 and -$6.7 million in Q2 2022.